SLC5A2 and hydrops fetalis: We have specifically demonstrated that the SGLT2 inhibitor empagliflozin ameliorate adverse cardiac remodeling and enhance systolic function in HF animals even in non-diabetic model [44]; in fact our findings have been later corroborated by other groups [45,46], demonstrating a cardio-protective effect in non- DM models with cardiomyopathy [47].